GLP3R is a triple-agonist peptide targeting GLP-1, GIP, and glucagon receptors, investigated for its effects on metabolic health, weight reduction, and glycemic control.

Research Focus:

• Obesity and weight loss research
• Glycemic control and insulin sensitivity
• Energy expenditure studies
• Cardiometabolic health improvement

Sources:

Phase-2 obesity trial (NEJM): https://www.nejm.org/doi/full/10.1056/NEJMoa2306813

Triple-agonist rationale (Cell Metabolism commentary): https://www.cell.com/cell-metabolism/fulltext/S1550-4131(23)00288-9

Early clinical results (JAMA Network Open brief): https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2808042

⚠️ Disclaimer: For research use only. Not intended for human consumption. This information is provided for educational purposes and has not been evaluated by the FDA.